Valuation: Intellia Therapeutics, Inc.

Market Cap 1.72B 1.53B 1.42B 1.3B 2.45B 165B 2.47B 17.24B 6.68B 84.43B 6.45B 6.31B 271B P/E 2026 *
-3.84x
P/E 2027 * -4.64x
Enterprise Value 1.38B 1.23B 1.14B 1.04B 1.97B 133B 1.99B 13.85B 5.37B 67.81B 5.18B 5.07B 218B EV / Sales 2026 *
26.6x
EV / Sales 2027 * 10.6x
Free-Float
96.16%
Yield 2026 *
-
Yield 2027 * -
1 day-0.61%
1 week+4.34%
Current month+1.66%
1 month-3.92%
3 months-30.18%
6 months-6.63%
Current year+36.37%
1 week 11.33
Extreme 11.33
12.76
1 month 11.24
Extreme 11.2427
12.97
Current year 9.05
Extreme 9.05
18.48
1 year 7.95
Extreme 7.95
28.25
3 years 5.9
Extreme 5.9
34.87
5 years 5.9
Extreme 5.9
143.92
10 years 5.9
Extreme 5.9
202.73
Manager TitleAgeSince
Chief Executive Officer 68 01/01/2018
Director of Finance/CFO 51 22/07/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 68 01/07/2014
Chairman 63 01/02/2020
Director/Board Member 74 31/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/26 Sell

Chief Executive Officer

-2,785 0.0020%
22/07/26 Sell

Chief Financial Officer

-8,111 0.0058%
02/07/26 Sell

Chief Financial Officer

-4,677 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+1.16%+4.34%-40.02%-58.31% 1.72B
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.26%-0.09%+44.95%+102.42% 39.23B
Weighted average by Cap. +0.12%-0.82%+58.33%+129.08%

Financials

2026 *2027 *
Net sales 51.88M 46.1M 43.02M 39.21M 73.96M 4.99B 74.65M 521M 202M 2.55B 195M 191M 8.18B 126M 112M 105M 95.43M 180M 12.14B 182M 1.27B 491M 6.2B 474M 464M 19.91B
Net income -420M -373M -348M -317M -599M -40.38B -604M -4.22B -1.63B -20.64B -1.58B -1.54B -66.25B -374M -332M -310M -283M -533M -35.95B -538M -3.75B -1.45B -18.38B -1.4B -1.37B -58.98B
Net Debt -338M -300M -280M -256M -482M -32.51B -487M -3.39B -1.31B -16.62B -1.27B -1.24B -53.33B -376M -334M -312M -284M -536M -36.18B -541M -3.78B -1.46B -18.49B -1.41B -1.38B -59.35B
Logo Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
Employees
377
Date Price Change Volume
02/10/26 $12.26 +1.16% 4,503,688
01/10/26 $12.12 +0.50% 7,448,336
30/09/26 $12.06 +0.25% 5,318,300
29/09/26 $12.03 +5.34% 5,017,506
28/09/26 $11.42 -2.81% 3,299,994
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
12.26USD
Average target price
24.00USD
Spread / Average Target
+95.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTLA Stock